Latest From RaNeDis Pharmaceuticals
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- RaNeDis Pharmaceuticals
- Senior Management
William Claypool, MD, Pres. & CEO
Ivan Joseph, CFO
Carrie Frey, COO
- Contact Info
Phone: (484) 445-4296
1400 N. Providence Rd., Bldg. 1,
Media, PA 19063
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.